New drugs: approval, benefit assessment, coverage

The first preoccupation with the question as to how a new drug reaches patients can be confusing: What is the point of a benefit assessment if the efficacy of a drug has already been evaluated during drug development and approval? Who decides on coverage and who sets the prices? Is the procedure the same in all of Europe as it is in Germany? And in the USA? The texts and graphs in this issue of "In focus" are designed to help you get started.

1. Drug approval and early benefit assessment in Germany

2. Drug approval and benefit assessment in other countries

3. The AMNOG procedure: more than just cost control

4. Particular therapeutic systems and traditional drugs

5. The institutions

Picture of

Jens Flintrop

press officer

Picture of

Susanne Breuer

press officer

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.